Fast Track in UK: Fast track approval may take a
Post# of 155561
(Total Views: 847)
Posted On: 09/10/2020 10:29:20 AM
Fast Track in UK:
Fast track approval may take a diff. path than PIM & EAMS route. I don't think the UK would be looking to simply make LL more readily accessible for clinical trial purposes, for free, as the PIM/EAMS route seems to indicate. I think the meeting for fast track approval, is exactly that, "approval". Not Emergency use, not a promising medicine, but approval, period. If the UK is serious about getting a therapeutic, they will find a way to get this into the general population asap - my guess is that is what was discussed - not "how do we fill out your online forms for PIM & EAMS access".
Selling it Politically:
Recall the lockdowns were to buy us time to cushion the healthcare system impact & help us learn how to treat the disease and arrive at a vaccine. The 1st 2 sorta happened, but not the vaccine "yet". Easy message to sell --> "We are very close to a vaccine but want to make sure it is safe & effective and not rushed. In the interim, we have a safe & effective therapeutic as proven out by the gold-standard of clinical trials that will help us treat patients quicker, minimize hospital stays & healthcare system impacts, and avoid economically damaging lockdowns until we arrive at a vaccine in the near future" - this avoids making it seem like the gov wasted their $$ on vaccine / OWS and makes it seem like they did a good job on the treatment portion.
Comp vote:
Still undecided but food for thought - Nader has shown no signs of misusing investors money and trust to the best of his ability (as a small biotech with little financing leverage, no revenues, and an arduous path to success). He has repeatedly said during calls how he won't reverse split, how he is doing everything he can to avoid dilution, and how he wants to reward the investors who have stuck by his side. The board members, from what I can tell, are good human beings, not driven by greed but moreso the desire to help people. You are investing in LL as much as you are investing in the management team/board. Do you want to vote for or against their judgment and recommendation? Do you think that giving them the flexibility to grow for the next 5-10 years into something real & tangible will be misused and abused in the next 6-12 months as one big "Hah! I gotcha!"? Again, I'm undecided but just one way to think about things... Just because they have the option doesn't mean they will use it.
Technical thought of the day:
We closed 4.44 3 days ago and then gapped up. It's very normal to "fill the gap" (as opposed to minding the gap) on stock charts. If it holds then that's typically a very good sign (i.e. Buyers who missed the RANTES boat the first time still have their boarding passes in hand for the 2nd trip - aka buyer interest still exists at that support level)
But I don't think any of us longs care about the technicals on this name as they ultimately have little bearing on the story.
L&S from the owner of the "Better Late than Never" towboat owner for the 29-center and 2.90 boats
Fast track approval may take a diff. path than PIM & EAMS route. I don't think the UK would be looking to simply make LL more readily accessible for clinical trial purposes, for free, as the PIM/EAMS route seems to indicate. I think the meeting for fast track approval, is exactly that, "approval". Not Emergency use, not a promising medicine, but approval, period. If the UK is serious about getting a therapeutic, they will find a way to get this into the general population asap - my guess is that is what was discussed - not "how do we fill out your online forms for PIM & EAMS access".
Selling it Politically:
Recall the lockdowns were to buy us time to cushion the healthcare system impact & help us learn how to treat the disease and arrive at a vaccine. The 1st 2 sorta happened, but not the vaccine "yet". Easy message to sell --> "We are very close to a vaccine but want to make sure it is safe & effective and not rushed. In the interim, we have a safe & effective therapeutic as proven out by the gold-standard of clinical trials that will help us treat patients quicker, minimize hospital stays & healthcare system impacts, and avoid economically damaging lockdowns until we arrive at a vaccine in the near future" - this avoids making it seem like the gov wasted their $$ on vaccine / OWS and makes it seem like they did a good job on the treatment portion.
Comp vote:
Still undecided but food for thought - Nader has shown no signs of misusing investors money and trust to the best of his ability (as a small biotech with little financing leverage, no revenues, and an arduous path to success). He has repeatedly said during calls how he won't reverse split, how he is doing everything he can to avoid dilution, and how he wants to reward the investors who have stuck by his side. The board members, from what I can tell, are good human beings, not driven by greed but moreso the desire to help people. You are investing in LL as much as you are investing in the management team/board. Do you want to vote for or against their judgment and recommendation? Do you think that giving them the flexibility to grow for the next 5-10 years into something real & tangible will be misused and abused in the next 6-12 months as one big "Hah! I gotcha!"? Again, I'm undecided but just one way to think about things... Just because they have the option doesn't mean they will use it.
Technical thought of the day:
We closed 4.44 3 days ago and then gapped up. It's very normal to "fill the gap" (as opposed to minding the gap) on stock charts. If it holds then that's typically a very good sign (i.e. Buyers who missed the RANTES boat the first time still have their boarding passes in hand for the 2nd trip - aka buyer interest still exists at that support level)
But I don't think any of us longs care about the technicals on this name as they ultimately have little bearing on the story.
L&S from the owner of the "Better Late than Never" towboat owner for the 29-center and 2.90 boats
(6)
(1)